Contribute Try STAT+ Today

Good morning, fellow humans. Erin Brodwin here, filling in for Ed Silverman. My unofficial mascot, a 25-pound pup named Dax, has fallen asleep to the sound of my typing as I sip away at my usual cup of Bolivian Fair Trade Certified coffee. The only flavored coffee I’ve ever tried is hazelnut, and one taste of that saccharin brew was enough to pull me back to the regular stuff. Here’s hoping your day is neither bitter nor overly sweet. On to the day’s news. …

A U.S. judge in the Purdue Pharma bankruptcy case plans to rule on the company’s request to approve its opioid settlement by week’s end, Reuters reports. The judge, New York-based Robert Drain, said he expected to make a ruling on Friday as to whether to approve Purdue’s request for a settlement related to its sale of opioids. The OxyContin maker claims the deal is worth more than $10 billion and has pledged $4.5 billion in exchange for legal protections against opioid-related lawsuits.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Create a display name to comment

This name will appear with your comment